- Home
- GCL vs ATAI Comparison
GCL vs ATAI Comparison
Compare GCL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCL
- ATAI
- Stock Information
- Founded
- GCL 2011
- ATAI 2018
- Country
- GCL Singapore
- ATAI Germany
- Employees
- GCL N/A
- ATAI N/A
- Industry
- GCL
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GCL
- ATAI Health Care
- Exchange
- GCL NYSE
- ATAI Nasdaq
- Market Cap
- GCL 250.7M
- ATAI 282.6M
- IPO Year
- GCL N/A
- ATAI 2021
- Fundamental
- Price
- GCL $1.95
- ATAI $1.47
- Analyst Decision
- GCL
- ATAI Strong Buy
- Analyst Count
- GCL 0
- ATAI 3
- Target Price
- GCL N/A
- ATAI $10.50
- AVG Volume (30 Days)
- GCL 41.5K
- ATAI 1.8M
- Earning Date
- GCL 01-01-0001
- ATAI 05-14-2025
- Dividend Yield
- GCL N/A
- ATAI N/A
- EPS Growth
- GCL N/A
- ATAI N/A
- EPS
- GCL N/A
- ATAI N/A
- Revenue
- GCL $112,351,837.00
- ATAI $308,000.00
- Revenue This Year
- GCL N/A
- ATAI $65.58
- Revenue Next Year
- GCL N/A
- ATAI N/A
- P/E Ratio
- GCL N/A
- ATAI N/A
- Revenue Growth
- GCL 25.23
- ATAI N/A
- 52 Week Low
- GCL $1.76
- ATAI $1.03
- 52 Week High
- GCL $15.55
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- GCL N/A
- ATAI 52.47
- Support Level
- GCL N/A
- ATAI $1.15
- Resistance Level
- GCL N/A
- ATAI $1.44
- Average True Range (ATR)
- GCL 0.00
- ATAI 0.13
- MACD
- GCL 0.00
- ATAI 0.03
- Stochastic Oscillator
- GCL 0.00
- ATAI 88.89
About GCL GCL GLOBAL HOLDINGS LTD
GCL Global Holdings Ltd is a provider of games and entertainment content based in Asia. The company unites people through games and entertainment experiences, enabling creators to deliver engaging content and fun gameplay experiences to the gaming communities across the globe, with a strategic focus on the rapidly expanding Asian gaming market. Its mission is to bridge cultures and audiences by introducing Asian-developed IP to a multinational audience across consoles, PCs and streaming platforms.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.